Efficacy of pollen immunotherapy in seasonal allergic rhinitis

Basit Öğe Kaydı
dc.contributor.authorCan, Demet
dc.contributor.authorTanac, Remziye
dc.contributor.authorDemir, Esen
dc.contributor.authorGulen, Figen
dc.contributor.authorVeral, Ali
dc.date.accessioned2019-10-27T19:36:36Z
dc.date.available2019-10-27T19:36:36Z
dc.date.issued2007
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground:The efficacy of subcutaneous pollen immunotherapy has been documented in published double-blind, placebo-controlled studies related to treatment of seasonal allergic rhinitis. In the present study, subjective (symptom scores) and objective (nasal peak inspiratory flow, nasal smear, nasal biopsy) parameters were used to study the efficacy of pollen immunotherapy. Methods: Forty-eight patients (32 male), mean +/- SE age 13.6 +/- 2.8 years allergic to grass-pollen participated in the present study. Patients were divided into three groups: group I, 24 patients who did not receive pollen immunotherapy; group II, 12 patients who received the build-up phase of pollen immunotherapy; and group III, 12 patients who had just finished pollen immunotherapy. With regard to objective and subjective parameters these three groups were compared. Results:When group I was compared to groups II and III, the patients who had not received any immunotherapy were found to have a high daytime nasal symptoms score (P < 0.01), high daytime eye symptoms score(P < 0.01) and high night-time symptoms score (P < 0.01). In objective parameters, it was found that group I had low nasal peak inspiratory flow (P < 0.05), and a high eosinophil count in nasal smears (P < 0.05) and peripheral blood (P < 0.05). It was also demonstrated that there was an increased eosinophil infiltration (P < 0.01) and mast cell infiltration (P < 0.05) in nasal biopsy in group I. There was no significant difference between group II and group III according to these results (P > 0.05). Conclusions: Immunotherapy leads to a better clinical and histopathological prognosis in children with seasonal allergic rhinitis.en_US
dc.identifier.doi10.1111/j.1442-200X.2007.02307.xen_US
dc.identifier.endpage69en_US
dc.identifier.issn1328-8067
dc.identifier.issn1442-200X
dc.identifier.issue1en_US
dc.identifier.pmid17250508en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage64en_US
dc.identifier.urihttps://doi.org/10.1111/j.1442-200X.2007.02307.x
dc.identifier.urihttps://hdl.handle.net/11454/39874
dc.identifier.volume49en_US
dc.identifier.wosWOS:000243637000013en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofPediatrics Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectallergic rhinitisen_US
dc.subjectimmunotherapyen_US
dc.subjectnasal biopsyen_US
dc.subjectnasal peak inspiratory flowen_US
dc.titleEfficacy of pollen immunotherapy in seasonal allergic rhinitisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu